Universität zu Köln

Equey, Tristan ORCID: 0000-0001-5369-9642, Pastor, Antoni, de la Torre Fornell, Rafael, Thomas, Andreas, Giraud, Sylvain ORCID: 0000-0002-3437-0849, Thevis, Mario, Kuuranne, Tiia, Baume, Norbert ORCID: 0000-0002-4028-8585, Barroso, Osquel and Aikin, Reid (2022). Application of the Athlete Biological Passport Approach to the Detection of Growth Hormone Doping. J. Clin. Endocrinol. Metab., 107 (3). S. 649 - 660. WASHINGTON: ENDOCRINE SOC. ISSN 1945-7197

Full text not available from this repository.

Abstract

Context Because of its anabolic and lipolytic properties, growth hormone (GH) use is prohibited in sport. Two methods based on population-derived decision limits are currently used to detect human GH (hGH) abuse: the hGH Biomarkers Test and the Isoforms Differential Immunoassay. Objective We tested the hypothesis that longitudinal profiling of hGH biomarkers through application of the Athlete Biological Passport (ABP) has the potential to flag hGH abuse. Methods Insulin-like growth factor 1 (IGF-1) and procollagen III peptide (P-III-NP) distributions were obtained from 7 years of anti-doping data in elite athletes (n = 11 455) and applied as priors to analyze individual profiles from an hGH administration study in recreational athletes (n = 35). An open-label, randomized, single-site, placebo-controlled administration study was carried out with individuals randomly assigned to 4 arms: placebo, or 3 different doses of recombinant hGH. Serum samples were analyzed for IGF-1, P-III-NP, and hGH isoforms and the performance of a longitudinal, ABP-based approach was evaluated. Results An ABP-based approach set at a 99% specificity level flagged 20/27 individuals receiving hGH treatment, including 17/27 individuals after cessation of the treatment. ABP sensitivity ranged from 12.5% to 71.4% across the hGH concentrations tested following 7 days of treatment, peaking at 57.1% to 100% after 21 days of treatment, and was maintained between 37.5% and 71.4% for the low and high dose groups 1 week after cessation of treatment. Conclusion These findings demonstrate that longitudinal profiling of hGH biomarkers can provide suitable performance characteristics for use in anti-doping programs.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Equey, Tristan UNSPECIFIED orcid.org/0000-0001-5369-9642 UNSPECIFIED Pastor, Antoni UNSPECIFIED UNSPECIFIED UNSPECIFIED de la Torre Fornell, Rafael UNSPECIFIED UNSPECIFIED UNSPECIFIED Thomas, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED Giraud, Sylvain UNSPECIFIED orcid.org/0000-0002-3437-0849 UNSPECIFIED Thevis, Mario UNSPECIFIED UNSPECIFIED UNSPECIFIED Kuuranne, Tiia UNSPECIFIED UNSPECIFIED UNSPECIFIED Baume, Norbert UNSPECIFIED orcid.org/0000-0002-4028-8585 UNSPECIFIED Barroso, Osquel UNSPECIFIED UNSPECIFIED UNSPECIFIED Aikin, Reid UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-688902
DOI:	10.1210/clinem/dgab799
Journal or Publication Title:	J. Clin. Endocrinol. Metab.
Volume:	107
Number:	3
Page Range:	S. 649 - 660
Date:	2022
Publisher:	ENDOCRINE SOC
Place of Publication:	WASHINGTON
ISSN:	1945-7197
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language GH-DEPENDENT MARKERS; FACTOR-I; INTRAINDIVIDUAL VARIATION; FACTOR AXIS; COLLAGEN TURNOVER; PRO-COLLAGEN; IGF-I; ABUSE; EXERCISE; SPORT Multiple languages Endocrinology & Metabolism Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/68890